The data presented on this page does not represent the view of Inform Diagnostics and its employees or that of Zippia. None of the information on this page has been provided or approved by Inform Diagnostics. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. The employee data is based on information from people who have self-reported their past or current employments at Inform Diagnostics. Piper Sandler acted as exclusive financial adviser for the acquisition, while Mintz Levin, Cohn, Ferris, Glovsky, and Popeo served as legal counsel to Fulgent Genetics, and Kirkland & Ellis served as legal counsel to Inform Diagnostics.Zippia gives an in-depth look into the details of Inform Diagnostics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Inform Diagnostics. Specifically, Fulgent expects core revenue for fiscal year 2022 to be approximately $175 million, compared to previous guidance of $120 million, which the firm said includes potential revenue contribution from the proposed acquisition. "We expect to see an immediate contribution from Inform Diagnostics' mature pathology business, while in the longer term we also believe there are numerous synergies across our organizations that will drive sustained momentum across Fulgent's core testing business," Hsieh said. Fulgent also expects to offer NGS-based oncology services to Inform Diagnostics' hematology clients. It also extends Fulgent's in-network managed care relationships to over 300 million covered lives as well as adds CLIA-, CAP-, and New York State-certified laboratories in Irving, Boston, New York City, and Phoenix.įulgent said it can now leverage Inform's "nationwide client base, established commercial organization, and managed care relationships" to expand the reach of its existing services, including a menu of customizable genomic tests for more than 18,400 genes.įulgent highlighted cross-selling opportunities with Inform Diagnostics' national gastrointestinal and genitourinary specialist client base, including for Fulgent's newly launched liquid biopsy test for hepatocellular carcinoma, HelioLiver, as well as for an upcoming molecular test for urology. The acquisition expands Fulgent's test menu into breast pathology, gastrointestinal pathology, dermatopathology, urologic pathology, neuropathology, and hematopathology, the firm said. "We have been impressed with the Inform Diagnostics team's commitment to quality, turnaround time, and customer service, which we believe fits well with our priorities, culture, and focus at Fulgent," Ming Hsieh, chairman and CEO of Fulgent, said in a statement. It is a portfolio company of Avista Capital Partners based in Irving, Texas. Inform Diagnostics currently provides pathology services to approximately 1,300 clients who represent over 2,700 physicians. On average, analysts are estimating first quarter revenues of $244.7 million. This exceeds prior guidance of $245 million and includes $22 million of core revenues excluding next-generation sequencing (NGS)-based COVID-19 testing. The firm also announced that it will acquire pathology laboratory Inform Diagnostics for $170 million in cash.įulgent's revenues for the quarter ended March 31 are expected to be approximately $300 million. NEW YORK – Fulgent Genetics reported on Monday estimated preliminary first quarter revenues above prior guidance. Advances in Clinical Genomics Profiling.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |